Shadan Lalezari

602 total citations
38 papers, 445 citations indexed

About

Shadan Lalezari is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Shadan Lalezari has authored 38 papers receiving a total of 445 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 7 papers in Genetics and 6 papers in Molecular Biology. Recurrent topics in Shadan Lalezari's work include Hemophilia Treatment and Research (31 papers), Blood Coagulation and Thrombosis Mechanisms (16 papers) and Platelet Disorders and Treatments (9 papers). Shadan Lalezari is often cited by papers focused on Hemophilia Treatment and Research (31 papers), Blood Coagulation and Thrombosis Mechanisms (16 papers) and Platelet Disorders and Treatments (9 papers). Shadan Lalezari collaborates with scholars based in Israel, United States and Germany. Shadan Lalezari's co-authors include Monika Maas Enriquez, Heinz Delesen, Anita Shah, Nurit Magal, Mordechai Shohat, Tamar Shohat, Yochai Birnbaum, Mark T. Reding, Aviv Mager and Yehuda Adler and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Shadan Lalezari

32 papers receiving 440 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shadan Lalezari Israel 13 344 82 81 58 58 38 445
Helen Pergantou Greece 10 276 0.8× 64 0.8× 29 0.4× 28 0.5× 51 0.9× 28 337
D. E. Mueller-Wiefel Germany 8 146 0.4× 106 1.3× 96 1.2× 19 0.3× 44 0.8× 9 447
Ihosvany Fernández Bello Spain 13 300 0.9× 49 0.6× 49 0.6× 25 0.4× 41 0.7× 36 391
Amie Fonder United States 8 112 0.3× 194 2.4× 81 1.0× 23 0.4× 13 0.2× 31 291
Ghaith Abu‐Zeinah United States 7 98 0.3× 145 1.8× 96 1.2× 118 2.0× 16 0.3× 44 254
A. Bernhardt Germany 9 208 0.6× 102 1.2× 188 2.3× 11 0.2× 55 0.9× 13 395
Yulia Volchek Israel 9 204 0.6× 99 1.2× 28 0.3× 28 0.5× 10 0.2× 29 285
Marie Bak Denmark 9 121 0.4× 182 2.2× 108 1.3× 78 1.3× 96 1.7× 15 322
Kazumasa Ohmura Japan 10 95 0.3× 13 0.2× 29 0.4× 141 2.4× 11 0.2× 22 240
Rebecca Bolce United States 12 107 0.3× 37 0.5× 30 0.4× 377 6.5× 17 0.3× 57 432

Countries citing papers authored by Shadan Lalezari

Since Specialization
Citations

This map shows the geographic impact of Shadan Lalezari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shadan Lalezari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shadan Lalezari more than expected).

Fields of papers citing papers by Shadan Lalezari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shadan Lalezari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shadan Lalezari. The network helps show where Shadan Lalezari may publish in the future.

Co-authorship network of co-authors of Shadan Lalezari

This figure shows the co-authorship network connecting the top 25 collaborators of Shadan Lalezari. A scholar is included among the top collaborators of Shadan Lalezari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shadan Lalezari. Shadan Lalezari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cohen, Omri, Ophira Salomon, Shadan Lalezari, et al.. (2025). Direct oral anticoagulants in patients with severe inherited thrombophilia: Real-world data from a tertiary care center. SHILAP Revista de lepidopterología. 18. 100201–100201.
2.
Lubetsky, Aharon, et al.. (2025). Acquired Hemophilia—A Case Series and Review. Journal of Clinical Medicine. 14(5). 1597–1597.
3.
Neuman, Yoram, Omri Cohen, Shadan Lalezari, et al.. (2025). Age‐Specific Differences in Cerebral Sinus Venous Thrombosis: A Retrospective Cohort Study From a Tertiary Care Center. Pediatric Blood & Cancer. 72(10). e31941–e31941.
4.
Reding, Mark T., Shadan Lalezari, Gili Kenet, et al.. (2024). Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review. Drugs in R&D. 24(3). 359–381. 3 indexed citations
5.
Budnik, Ivan, Omri Cohen, Tami Brutman‐Barazani, et al.. (2024). The Impact of Emicizumab Prophylaxis on Hospitalizations and Emergency Department Visits Among Hemophilia A Patients Is Age Related. Pediatric Blood & Cancer. 72(2). e31456–e31456.
6.
Cohen, Omri, Sarina Levy‐Mendelovich, Ivan Budnik, et al.. (2023). Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center. Research and Practice in Thrombosis and Haemostasis. 7(6). 102178–102178. 3 indexed citations
7.
Dardik, Rima, Szymon Janczar, Shadan Lalezari, et al.. (2023). Four Decades of Carrier Detection and Prenatal Diagnosis in Hemophilia A: Historical Overview, State of the Art and Future Directions. International Journal of Molecular Sciences. 24(14). 11846–11846. 4 indexed citations
8.
9.
Reding, Mark T., Ingrid Pabinger, Pål André Holme, et al.. (2021). Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study. Haemophilia. 27(3). e347–e356. 15 indexed citations
10.
Santagostino, Elena, Shadan Lalezari, Mark T. Reding, et al.. (2021). Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A. Haemophilia. 27(4). e559–e562. 6 indexed citations
11.
Lalezari, Shadan, et al.. (2020). Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis. Advances in Therapy. 37(6). 2763–2776. 1 indexed citations
12.
Lalezari, Shadan, Mark T. Reding, Ingrid Pabinger, et al.. (2019). BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. Haemophilia. 25(6). 1011–1019. 22 indexed citations
13.
Santagostino, Elena, Shadan Lalezari, Mark T. Reding, et al.. (2019). Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial. Thrombosis Research. 183. 13–19. 23 indexed citations
14.
Appel, Sarit, et al.. (2017). Acquired Hemophilia A in a Patient with Non-Small Cell Lung Carcinoma: A Rare Paraneoplastic Phenomenon.. PubMed. 19(2). 128–130. 2 indexed citations
15.
Oldenburg, Johannes, Jerzy Windyga, K. K. Hampton, et al.. (2016). Safety and efficacy of BAY 81‐8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia. 22(3). 349–353. 15 indexed citations
16.
Lalezari, Shadan, U. Martinowitz, Jerzy Windyga, et al.. (2013). Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three‐times‐weekly prophylaxis with rFVIII‐FS. Haemophilia. 20(1). e15–22. 32 indexed citations
17.
18.
Strauss, Tzipora, Aharon Lubetsky, B. Ravid, et al.. (2011). Recombinant factor concentrates may increase inhibitor development: a single centre cohort study. Haemophilia. 17(4). 625–629. 23 indexed citations
19.
Maor‬‏, ‪Yasmin, Dalia Bashari, Gili Kenet, et al.. (2006). Hepatitis C at the Israeli National Hemophilia Center. Haemophilia. 12(1). 68–74. 14 indexed citations
20.
Amiel, Aliza, et al.. (2002). Allele-specific replication associated with aneuploidy in blood cells of patients with hematologic malignancies. Cancer Genetics and Cytogenetics. 139(2). 97–103. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Helen Pergantou Breakdown of academic impact, for papers by D. E. Mueller-Wiefel Breakdown of academic impact, for papers by Ihosvany Fernández Bello Breakdown of academic impact, for papers by Amie Fonder Breakdown of academic impact, for papers by Ghaith Abu‐Zeinah Breakdown of academic impact, for papers by A. Bernhardt Breakdown of academic impact, for papers by Yulia Volchek Breakdown of academic impact, for papers by Marie Bak Breakdown of academic impact, for papers by Kazumasa Ohmura Breakdown of academic impact, for papers by Rebecca Bolce
Rankless by CCL
2026